secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117308
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports Q3 net loss of $3.6M; positive Phase 2 data for ELX-02; Nasdaq delisting appeal pending
--------------------------------------------------------------------------------

- Net loss of $3.6M ($1.31/share) vs. $7.5M loss a year ago; R&D expenses down to $1.3M from $4.9M.
- Cash of $4.8M as of Sep 30; raised $3.8M in Q3; cash expected to fund operations only through end of Q4 2023.
- Phase 2 open-label trial of ELX-02 in Alport Syndrome showed improved kidney morphology, collagen expression, and average 60% increase in filtration slit density.
- Strategic partnership progress for ZKN-013; FDA clearance received for single ascending dose trial.
- Common stock suspended on Nasdaq on Oct 16 and now trades on OTC Pink; appeal of delisting decision pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/0001104659-23-117308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923117308/tm2330576d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer